Neurocrine Biosciences director proposes $2.15M sale

Morgan Stanley Smith Barney LLC is identified as broker, and NASDAQ is listed for the proposed sale.

Available on EDGAR 11/02/2026 - 04:38 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

George Morrow, a director of Neurocrine Biosciences, Inc. (NBIX), gave notice of a proposed sale of 14,700 common shares, with an aggregate market value of $2,147,670.00. The notice says the shares were and will be received through stock-option exercises over the next three months, with acquisition and payment dates corresponding to exercise and sale dates.

A past-three-months table lists Morrow's sale of 300 shares on October 30, 2026, for $44,700.00.

Key Figures

Common shares proposed for sale: 14,700 shares Aggregate market value: $2,147,670.00 Shares outstanding: 101,649,181 shares +3 more

6 metrics

Common shares proposed for sale 14,700 shares Proposed sale

Aggregate market value $2,147,670.00 Proposed sale

Shares outstanding 101,649,181 shares Listed in the securities information table

Prior shares sold 300 shares October 30, 2026

Aggregate value of prior sale $44,700.00 October 30, 2026

Stock-option exercise period Three months Shares to be received upon exercise of stock options

Key Terms

Rule 144, Exercise of Stock Options, 10b5-1 Sales

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Exercise of Stock Options"

10b5-1 Sales regulatory

"10b5-1 Sales for GEORGE MORROW"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NBIX shares did George Morrow propose to sell?

George Morrow, a director, reported a proposed sale of 14,700 common shares, with an aggregate market value of $2,147,670.00.

What prior NBIX share sale did George Morrow report?

The past-three-months table lists a sale of 300 common shares on October 30, 2026, for $44,700.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001068754
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NEUROCRINE BIOSCIENCES, INC.
SEC File Number	000-22705
Address of Issuer	6027 Edgewood Bend Court San Diego CALIFORNIA 92130
Phone	8586177600
Name of Person for Whose Account the Securities are To Be Sold	GEORGE MORROW
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	14700	2147670.00	101649181	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/02/2026	Exercise of Stock Options	Issuer			14700	11/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for GEORGE MORROW 6027 Edgewood Bend Court San Diego CA 92130	Common	10/30/2026	300	44700.00

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	11/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ George Morrow
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)